EXHIBIT 3.1
|
1 |
|
|
|
2 |
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 10, 2018
|
BioCorRx Inc. |
|
(Exact name of registrant as specified in its charter) |
|
Nevada |
|
000-54208 |
|
90-0967447 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employee Identification No.) |
2390 East Orangewood Avenue, Suite 575
Anaheim, California 92806
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (714) 462-4880
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
|
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On May 10, 2018, BioCorRx Inc. (the “Company”) filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada (the “Certificate of Amendment”) increasing the total number of shares which the Company is authorized to issue from five hundred twenty five million six hundred thousand (525,600,000) shares to seven hundred fifty million six hundred thousand (750,600,000) shares and increasing the number of authorized shares of common stock from five hundred and twenty five million (525,000,000) shares of common stock to seven hundred and fifty million (750,000,000) shares of common stock.
A copy of the Certificate of Amendment is included as Exhibit 3.1 to this Report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
|
|
||
|
2 |
|
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BIOCORRX INC. |
||
|
|
|||
|
Date: May 16, 2018 |
By: |
/s/ Lourdes Felix |
|
|
|
Lourdes Felix |
||
|
|
Chief Financial Officer |
||
|
3 |
EXHIBIT 3.1
|
1 |
|
|
|
2 |